Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria

Abstract

This invention provides materials and procedures for the delivery of selected strains of bacteria and/or oxalate-degrading enzymes to the intestinal tracts of persons who are at increased risk for oxalate related disease because they have lost, or have inadequate concentrations of these bacteria. The administration of these bacteria and/or the relevant enzyme removes oxalate from the intestinal tract and thus reduces the amount of oxalate available for absorption and reduces the risk for oxalate related disease.

1. A method for the prophylaxis or treatment of hyeroxaluria and the disorders associated therewith which comprises administrating to an animal in need thereof from 0.5 to 4 g/day of a bacterial combination composition comprising:
 (a) Streptococcus thermophilus in admixture with  
 (b) at least one bacterial strain selected from the group consisting of Lactobacillus brevis, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium breve or mixtures thereof.  
 
     
     
       2. The method of  claim 1 , wherein the strain of Lactobacillus brevis is DSM 11988 or mutants and derivatives thereof. 
     
     
       3. The method of  claim 1 , wherein the ratio of the concentration of Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium breve in the mixture, expressed in CFU/g of composition, are 1:1:1. 
     
     
       4. The method of  claim 1 , wherein the ratio of the concentrations of Streptococcus thermophilus and the Lactobacillus strain, expressed in CFU/g of composition, is from 1000:1 to 1:1000. 
     
     
       5. The method of  claim 1 , wherein the ratio of the concentrations of Streptococcus thermophilus and the Bifidobacterium strain, expressed in CFU/g of composition, is from 1000:1 to 1:1000. 
     
     
       6. A method for the prophylaxis or treatment of hyperoxaluria and the disorders associated therewith comprises administrating to a subject in need thereof from  0 . 5  to  4  g/day of a bacterial combination composition comprising:
   (a) Streptococcus thermophilus in admixture with        (b) at least one bacterial strain selected from the group consisting of Lactobacillus brevis, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium breve or mixtures thereof.     
     
     
       7. The method of  claim 6 , wherein the subject is a human. 
     
     
       8. A dietary or pharmaceutical composition comprising at least one strain of a bacteria selected from the group consisting of Streptococcus thermophilis, Lactobacillus brevis, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium breve in combination with a hyperoxaluria-inducing drug. 
     
     
       9. The composition of  claim 8 , in which the drug is orlistat.